---
mi_id: MIPR-node_b37cdfe
type: press_release
canonical_url: "https://www.pheonixresearch.com/healthcare/medical-devices/press-release/pharmacy-automation-6180-million-pharmacy-count-fell-8000/"
md_url: "https://www.pheonixresearch.com/healthcare/medical-devices/press-release/pharmacy-automation-6180-million-pharmacy-count-fell-8000.md"

schema:
  "@type": NewsArticle
  "@id": MIPR-node_b37cdfe
  url: "https://www.pheonixresearch.com/healthcare/medical-devices/press-release/pharmacy-automation-6180-million-pharmacy-count-fell-8000/"
  title: "Pheonix Research Releases 2026–2033 Pharmacy Automation Forecast: USD 6.18 Billion Today, USD 11.24 Billion by 2033, With 8,000 Fewer Pharmacies Buying It"
  description: "Pheonix Research: the pharmacy automation system market is USD 6,180m in 2025 and USD 11,240m by 2033 at 7.76%, while units grow only 4.90% as pharmacy numbers fall."
  datePublished: "2026-11-18T14:05:09+00:00"
  dateModified: "2026-11-18T16:50:55+00:00"
  isPartOf:
    - id: MISG-node_f29f33b
      type: CollectionPage
      url: "https://www.pheonixresearch.com/healthcare/medical-devices/"
      name: Medical Devices
    - id: MIIN-node_50b4dbf
      type: CollectionPage
      url: "https://www.pheonixresearch.com/healthcare/"
      name: Healthcare
    - id: MIWS-root
      type: WebSite
      url: "https://www.pheonixresearch.com/"
      name: Pheonix Research

acf:
  phoenix_meta_title: "Pharmacy Automation Reaches USD 6,180 Million While the Pharmacy Count Falls by 8,000"
  phoenix_meta_description: "Pheonix Research: the pharmacy automation system market is USD 6,180m in 2025 and USD 11,240m by 2033 at 7.76%, while units grow only 4.90% as pharmacy numbers fall."

global_schema:
  organization:
    "@id": MIWS-root#organization
    "@type": Organization
    url: "https://www.pheonixresearch.com/"
    name: Pheonix Research
  website:
    "@id": MIWS-root
    "@type": WebSite
    url: "https://www.pheonixresearch.com/"
    name: Pheonix Research
  api:
    "@id": MIWS-root#api
    "@type": WebAPI
    url: "https://www.pheonixresearch.com/"

graph:
  node_id: MIPR-node_b37cdfe
  graph_node_endpoint: "https://graph.pheonixresearch.com/api/v1/query/live/node/MIPR-node_b37cdfe"
  graph_snapshot: "https://graph.pheonixresearch.com/api/v1/read/live/graph"
  graph_exclusions: "https://graph.pheonixresearch.com/api/v1/read/live/exclusions"
  graph_meta: "https://graph.pheonixresearch.com/api/v1/read/live/meta"
  graph_bundle: "https://graph.pheonixresearch.com/api/v1/read/live/bundle"

discovery:
  discovery_json: "https://www.pheonixresearch.com/.well-known/pheonix-discovery.json"
  llms_txt: "https://www.pheonixresearch.com/llms.txt"
  sitemap: "https://www.pheonixresearch.com/sitemap.xml"
---
# Pheonix Research Releases 2026–2033 Pharmacy Automation Forecast: USD 6.18 Billion Today, USD 11.24 Billion by 2033, With 8,000 Fewer Pharmacies Buying It

**Pheonix Research — Global pharmacy automation systems are a USD 6,180 million market in 2025 and reach USD 11,240 million by 2033, a 7.76 per cent CAGR,** according to a new report published today. Unit shipments rise from 62,400 systems to 91,500 over the same period, a 4.90 per cent CAGR, which means revenue per installed system grows from USD 99,038 to USD 122,842, or 2.73 per cent a year.

The gap between those two growth rates is the report's central finding. Pharmacy automation is no longer growing because more pharmacies are opening. It is growing because the pharmacies that remain are larger, the central-fill nodes that serve them are more heavily automated, and each installation now carries more software and more service than the machine it replaces.

"Value compounds half again as fast as volume, and it is not price inflation," said the Pheonix Research healthcare devices team. "It is mix. A health system that closes twenty-one hospital pharmacies and serves them from one robotic hub buys fewer machines and more automation per machine. That is the trade this market is now built on."

The buyer base is contracting in plain numbers. The United States has almost 8,000 fewer retail pharmacies than it did in 2018 and lost more than 2,000 in 2025 alone, with Rite Aid liquidated and Walgreens and CVS working through multi-year closure programmes. Yet total US prescription dispensing revenue across all formats reached a record USD 751 billion in 2025, up 10 per cent, because growth is concentrated in specialty drugs that are largely dispensed outside retail chains and supermarkets. Retail keeps the everyday generic script, roughly 90 per cent of its volume, on a reimbursement that deflates.

Behind the storefront, hospital automation is deep at the point of care and shallow everywhere else. In the 2023 ASHP national survey of 1,497 general and children's hospitals, 86.1 per cent used automated dispensing cabinets as their primary maintenance-dose distribution method. Central-pharmacy penetration collapses from there: 27.0 per cent had a high-density carousel, 6.5 per cent had a robot dispensing unit doses, 2.0 per cent used a robot as their primary central distribution method, 3.7 per cent used any automation for compounding sterile preparations, and 3.4 per cent used a robotic IV compounder. More than half — 52.7 per cent — reported no IV workflow technology at all for sterile preparation.

"The cabinet sale has largely been made and the compounding-suite sale has not," the team said. "That is why IV and sterile compounding automation grows at 10.10 per cent against 6.81 per cent for cabinets. It is also why the constraint on this market is not clinical appetite. It is capital, floor space, and the difficulty of rebuilding a pharmacy that cannot stop dispensing while you rebuild it."

Three vendors disclose enough revenue to reconcile against the model. Omnicell reported fiscal 2025 revenue of USD 1,185 million, up 7 per cent, and launched its Titan XT dispensing system at the ASHP 2025 Midyear Clinical Meeting. BD's Medication Management Solutions reported USD 835 million in the quarter ended 31 December 2025, within a Connected Care segment reorganised from 1 October 2025, and launched the Incada Connected Care Platform with next-generation Pyxis Pro alongside a first-of-its-kind US pharmacy automation partnership with Henry Ford Health around the Rowa Vmax robot. Tosho reported net sales of JPY 29.5 billion. Together these named pools carry 46.68 per cent of the 2025 base; the remaining 53.32 per cent sits in private and regional vendors.

The report sets out three scenarios. The base case reaches USD 11,240 million in 2033 at 7.76 per cent. A bull case at 9.31 per cent, reaching USD 12,600 million, requires sterile compounding automation to cross 10 per cent hospital penetration by 2030 and central-fill construction to pull forward. A bear case at 6.00 per cent, reaching USD 9,850 million, requires retail closure to outrun central-fill construction and hospital capital to defer one full refresh cycle. A single point off the 2.73 per cent realisation assumption — holding units constant — moves 2033 value to about USD 10,400 million.

"The most fragile number in this forecast is not the number of machines sold," the team said. "It is whether buyers pay for the analytics layer. Barcode verification of doses runs at 73.6 per cent of US hospitals and advanced analytics at 5.7 per cent. The subscription is being sold into a base that has not yet bought it."

The full report, *Global Pharmacy Automation System Market Report, Size, Share and Forecast 2026–2033: The Pharmacy Count Fell by Eight Thousand and Automation Grew Anyway*, is available at [pheonixresearch.com](https://www.pheonixresearch.com/healthcare/medical-devices/market-report/pharmacy-automation-system-market/). It covers market sizing and forecast by equipment family and region, the value chain and cost structure, the competitive landscape with a revenue reconciliation against disclosed vendor results, investment activity, technology and innovation, market risk and scenarios, and the regulatory landscape covering device clearance, USP <797> and <800>, and reimbursement. The report is built on a 70/30 split of secondary and primary research, uses no market-research competitor data as an input, and discloses each estimated pool against hard disclosure.

**About Pheonix Research.** Pheonix Research produces market intelligence on industrial, healthcare and technology markets, built on disclosed primary sources, a structured primary research programme, and a documented model in which every estimated figure is identified as an estimate.
